

## RECENT PUBLICATIONS

1. Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto M. Feasibility of Assaying Prostate Cancer Disease Burden with Shutter-Speed DCE-MRI. *Proc. Int. Soc. Magn. Reson. Med.* 20, 2993, (2012).
2. Li X, Priest RA, Woodward WJ, Siddiqui F, Beer TM, Garzotto MG, Rooney WD and Springer CS. Cell Membrane Water Exchange Effects in Prostate DCE-MRI. *J Mag Res* 2012 May; 218:77-85.
3. Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto MG, Springer CS. Feasibility of Shutter-Speed DCE-MRI for Improved Prostate Cancer Detection. *Magn Reson Med.* 2013 Jan;69(1):171-8.
4. Priest R, Garzotto M, Kaufman J: Benign prostatic hyperplasia: a brief overview of pathogenesis, diagnosis, and therapy. *Tech Vasc Interv Radiol.* 2012 Dec;15(4):261-4
5. Garzotto M, Hung A: Advances in the Multi-modality Management of High-risk Prostate Cancer: *Surg Oncol Clin N Am.* 2013 Apr;22(2):375-94.
6. Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, **Garzotto** MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. *Lancet Oncol.* 2013 Aug;14(9):893-900.
7. Ansbaugh N, Shannon J, Mori M, Farris PE, Garzotto M. Agent Orange as a risk factor for high-grade prostate cancer. *Cancer.* 2013 Jul 1;119(13):2399-404.
8. Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM.: Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. *Clin Cancer Res.* 2014 Mar 1;20(5):1306-12.
9. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol.* 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.
10. Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. *PLoS One.* 2014 Sep 8;9(9):e104271.